Revive Therapeutics - CEO, Michael Frank
CEO, Michael Frank
Source: E-Lab NYC
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Revive Therapeutics (CSE:RVV) is expanding the scope of a sponsored research partnership agreement with the University of Wisconsin-Madison
  • The partnership will evaluate new psilocybin formulations and include a Phase 1 clinical study to investigate the therapeutic applications of psilocybin
  • Research currently under way at the University is focused on tannin-chitosan composites in the form of thin films, hydrogels and 3D foams
  • Final formulations of the products will be assessed in pre-clinical and clinical studies relating to various diseases and disorders
  • Revive Therapeutics (RVV) is down 2.22 per cent and is trading at C$0.22 per share

Revive Therapeutics (CSE:RVV) is expanding the scope of a sponsored research partnership agreement with the University of Wisconsin-Madison.

Current research being carried out at the University of Wisconsin-Madison is focused on tannin-chitosan composites in the form of thin films, hydrogels and 3D foams. Revive noted that the tannin-chitosan composite thin films are the most promising candidate to deliver therapeutic doses of psilocybin into the oral cavity.

The research will include the development of various composite formulations, physio-chemical characterisation of the composite materials, and the rate of psilocybin release from these composites.

The final formulations of these products will be assessed in pre-clinical and clinical studies relating to a number of diseases and disorders.

Michael Frank, CEO of Revive Therapeutics, said that expanded partnership will serve as a platform to create unique psychedelic-based therapeutics for clinical research targeting specific medical needs, such as addiction use disorders.

He also noted that the work will help to create a robust product pipeline with the aim to pursue the FDA regulatory pathway for commercialisation.

In addition, Revive plans to finalise a sponsorship program regarding a Phase 1 clinical study, which will focus on assessing psilocybin as a potential treatment for an as-yet undisclosed addiction disorder.

The study will be undertaken at the University of Wisconsin-Madison’s School of Medicine and Public Health. It will also involve the School of Pharmacy, which holds a Wisconsin special authorisation and DEA-issued license to carry out clinical research with psilocybin.

Revive Therapeutics (RVV) is down 2.22 per cent and is trading at C$0.22 per share at 3:39pm EDT.

More From The Market Herald

" Irwin Naturals (CSE:IWIN) cannabis products launch nationwide in Canada

Irwin Naturals (IWIN) has released its new CBD 25mg softgels in Canada.

" Amazon (NASDAQ:AMZN) continues healthcare expansion with multi-billion-dollar deal

Amazon (NASDAQ:AMZN) has closed a multi-billion-dollar acquisition of primary care provider One Medical.

" Psyched Wellness’ (CSE:PSYC) Calm listed on the world’s largest c-commerce marketplace

Psyched Wellness’ (PSYC) top product Calm has been approved and listed on Amazon.com.

" Sona Nanotech (CSE:SONA) closes Siva Therapeutics acquisition

Sona Nanotech (SONA) has closed its acquisition of Siva Therapeutics.